Publications
845
Citations
31,597
Est. group size
~37
Recurring co-author estimate
Active years
32
Publishing since 1995
Alex Sparreboom's research focuses on how cancer drugs move through and interact with the body, particularly the role of membrane transporter proteins in drug absorption, distribution, and side effects. Much of the work examines drug-drug interactions, dosing safety in specific patient populations, and mechanisms behind chemotherapy-related nerve damage (neuropathy). The lab uses animal models and pharmacokinetic methods to inform safer, more personalized use of cancer treatments.
Output was relatively steady (single digits to twenties per year) from 2017-2022, then increased sharply in 2023 and has remained elevated through 2025-2026.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Ribociclib is not a substrate or inhibitor of Oatp1b-mediated uptake in vivo
Cancer Chemotherapy and Pharmacology · 2026
- Elucidating the Role of S100A9 in Paclitaxel-Induced Peripheral Neuropathy (Abstract ID: 274573)
Journal of Pharmacology and Experimental Therapeutics · 2026
- Environmental Pollutant PFOS Identified in Untargeted Metabolomics as a Dual Oatp1b Substrate and Inhibitor: Implications for DDI Risk (Abstract ID: 234146)
Journal of Pharmacology and Experimental Therapeutics · 2026
- Development of a Translationally Relevant Strategy to Protect Against Paclitaxel-Induced Peripheral Neuropathy (Abstract ID: 274568)
Journal of Pharmacology and Experimental Therapeutics · 2026
- Membrane transporters in drug development and as determinants of precision medicine
Nature Reviews Drug Discovery · 2024
- Vincristine Disposition and Neurotoxicity Are Unchanged in Humanized CYP3A5 Mice
Drug Metabolism and Disposition · 2023
- Exploring pharmacokinetics of talazoparib in ABCB1/ABCG2-deficient mice using a novel UHPLC-MS/MS method
Heliyon · 2023
- Unique Cabozantinib Dosing Considerations in People Living with HIV and Cancer
Clinical Cancer Research · 2023
- <i>DPYD</i> Testing: Time to Put Patient Safety First
Journal of Clinical Oncology · 2023
- Supplementary Figure 4 from Contribution of Abcc4-Mediated Gastric Transport to the Absorption and Efficacy of Dasatinib
2023
- Supplementary Figure 1 from Contribution of Abcc4-Mediated Gastric Transport to the Absorption and Efficacy of Dasatinib
2023
- Supplementary Figure 3 from Contribution of Abcc4-Mediated Gastric Transport to the Absorption and Efficacy of Dasatinib
2023
- Supplementary Figure 1 from Contribution of Abcc4-Mediated Gastric Transport to the Absorption and Efficacy of Dasatinib
2023
- Supplementary Figure 4 from Contribution of Abcc4-Mediated Gastric Transport to the Absorption and Efficacy of Dasatinib
2023
- Supplementary Figure 5 from Contribution of Abcc4-Mediated Gastric Transport to the Absorption and Efficacy of Dasatinib
2023
- Journal of Pharmacology and Experimental Therapeutics×19
- The FASEB Journal×11
- Clinical and Translational Science×8
- Journal of Chromatography B×8
- Nature Communications×6
- Deanna L. Kroetz
Medicine · The Ohio State University
- Alice A. Gibson
Medicine · The Ohio State University
- K. Sandy Pang
Medicine · Purdue University West Lafayette
- David R. Foster
Medicine · Purdue University West Lafayette
- Ming Hu
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile